Ushbu ish iqtibos qilgan ishlar

189 ta ish

Ish: Innovations in cancer immunotherapy: A comprehensive overview of recent breakthroughs and future directions

Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
Evanthia Galanis, Lynn C. Hartmann, William A. Cliby +17
Maqola20102 iqtibos
ABI
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Gregory L. Beatty, Andrew R. Haas, Marcela V. Maus +9
Maqola20132 iqtibos
ABI
Oncolytic Viruses: Exploiting Cancer's Deal with the Devil
Larissa A. Pikor, John C. Bell, Jean‐Simon Diallo
Sharh maqola20152 iqtibos
ABI
Harnessing the immune system to improve cancer therapy
Nikos E. Papaioannou, Ourania V. Beniata, Panagiotis Vitsos +2
Sharh maqola20162 iqtibos
ABI
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment
Hila Magen, Eli Muchtar
Sharh maqola20162 iqtibos
ABI
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
Larysa Sanchez, Yucai Wang, David S. Siegel +1
Sharh maqola20162 iqtibos
ABI
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González +30
Maqola20172 iqtibos
ABI
Cytokines in Cancer Immunotherapy
Thomas A. Waldmann
Sharh maqola20172 iqtibos
ABI
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo‐Jack, Alice T. Shaw
Sharh maqola20172 iqtibos
ABI
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Flávia Castro, Ana Patrícia Cardoso, Raquel M. Gonçalves +2
Sharh maqola20182 iqtibos
ABI
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
Jung-Mao Hsu, Weiya Xia, Yi‐Hsin Elsa Hsu +14
Maqola20182 iqtibos
ABI
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Jong‐Ho Cha, Wenhao Yang, Weiya Xia +25
Maqola20182 iqtibos
ABI
Role of the immunosuppressive microenvironment in immunotherapy
Garth W. Tormoen, Marka R. Crittenden, Michael J. Gough
Sharh maqola20182 iqtibos
ABI
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jérôme Galon, Daniela Bruni
Sharh maqola20192 iqtibos
ABI
Mechanisms of immunotherapy resistance: lessons from glioblastoma
Christopher M. Jackson, John Choi, Michael Lim
Sharh maqola20192 iqtibos
ABI
Extracellular Vesicle- and Extracellular Vesicle Mimetics-Based Drug Delivery Systems: New Perspectives, Challenges, and Clinical Developments
Prakash Gangadaran, Byeong‐Cheol Ahn
Sharh maqola20202 iqtibos
ABI
Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment
Lucia Lisi, Pedro Miguel Lacal, Maria Martire +2
Sharh maqola20212 iqtibos
ABI
VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment
Yueshui Zhao, Sipeng Guo, Jian Min Deng +13
Sharh maqola20222 iqtibos
ABI
Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study
Yongxian Hu, Yali Zhou, Mingming Zhang +25
Maqola20222 iqtibos
ABI
GPRC5D-Targeted CAR T Cells for Myeloma
Sham Mailankody, Sean M. Devlin, Jonathan Landa +35
Maqola20222 iqtibos
ABI
Sarlavhasiz
Boshqa1 iqtibos
ABI
Sarlavhasiz
Boshqa1 iqtibos
ABI
Sarlavhasiz
Boshqa1 iqtibos
ABI
Sarlavhasiz
Boshqa1 iqtibos
ABI
Sarlavhasiz
Boshqa1 iqtibos
ABI